$KYMR

Raymond James initiated coverage on Kymera Therapeutics (KYMR) with an Outperform rating and $140 price target, citing its drug pipeline and upcoming trial results. The stock has gained 94% over the past year but may be overvalued. Analysts maintain a bullish stance with targets ranging from $111 to $180. Recent updates from Citi, B.Riley, and Piper Sandler also highlight the company's potential.

Citigroup maintained its Buy rating on Kymera Therapeutics (KYMR) and raised its price target to $150 from $135. The company, which develops targeted protein degradation therapies, has a market cap of $9 billion. GuruFocus values KYMR at $41.35, suggesting a 161.8% overvaluation at its current price of $108.25. Insiders have sold over $10 million in shares recently.

Citi raised its price target for Kymera Therapeutics (KYMR) to $150 from $135, citing potential for its KT-621 drug in atopic dermatitis. The stock is up 85% over the past year. Citi expects $2.5B in peak sales by 2032. Other analysts also raised targets, with estimates ranging from $111 to $180.

Wells Fargo named 13 stocks across seven sectors for its 4Q 2026 long ideas, all rated 'overweight' with expected 10%+ returns. Key picks include Roblox (bookings guidance $2.01B-$2.07B), Occidental Petroleum, and Microsoft. Price targets and catalysts are provided for each.

Mainolfi Nello (Chief Executive Officer) sold 30,000 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $113.80 ($111.44–$116.12, $3.41M total) across 6 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

B.Riley reiterated a Buy rating and $155 price target for Kymera Therapeutics (KYMR) after new trial data. The stock is up 104% year-over-year. Analysts note potential for re-rating if BROADEN2 trial shows positive results. Multiple analysts have raised price targets, citing the Phase 2b study as a key catalyst.

Goldman Sachs resumed coverage on Kymera Therapeutics (KYMR) with an Early-Stage Biotech rating. The stock has surged 120% over the past year to $115.47, trading near its 52-week high of $130.05. Analysts have set price targets ranging from $125 to $170, citing ongoing clinical trials and financial status as key factors.

Kymera Therapeutics (KYMR) presented its focus on oral immunology at Citigroup's Biopharma Summit, highlighting STAT6 and IRF5 programs. STAT6 aims to treat type 2 inflammation, with Phase III readout expected by year-end 2024. IRF5 targets autoimmune diseases, with human genetics and biological validation. The company seeks to become an independent commercial entity, focusing on immunology. Kymera's stock is up 2.54% to $118.36.

Adams Brian (Chief Legal Officer) sold 6,371 shares of Kymera Therapeutics, Inc. (KYMR) at an average of $116.83 ($115.55–$117.57, $0.74M total) across 3 trades on 2026-09-04.

RBC Capital's Brian Abrahams maintained a Hold rating on Kymera Therapeutics (KYMR) with a $112 price target, while LifeSci Capital's Patrick Dolezal initiated coverage on vTv Therapeutics (VTVT) with a Buy rating and $60 target. KYMR's consensus price target is $135.22, and VTVT's is $58.50.